Description

Telma-CT 80/12.5 Tablet is a combination antihypertensive medicine designed for enhanced blood pressure control. It contains:

Telmisartan (80mg): An angiotensin II receptor blocker (ARB) that relaxes blood vessels, lowering blood pressure.
Chlorthalidone (12.5mg): A thiazide-like diuretic that removes excess salt and water, reducing blood volume and the heart’s workload.

This higher-strength combination is suitable for patients whose hypertension is not adequately controlled by lower doses or monotherapy, providing strong and sustained blood pressure management.

Uses of Telma-CT 80/12.5 Tablet

Management of high blood pressure (hypertension)
Reduces risk of stroke, heart attack, and cardiovascular complications
Helps manage fluid retention
Suitable for patients requiring stronger dual therapy

How to Take

Take once daily, preferably at the same time every day.
Can be taken with or without food.
Maintain adequate fluid intake unless restricted by your doctor.
Do not stop or adjust the dosage without consulting a healthcare professional.

Side Effects

Common:

Dizziness or lightheadedness
Increased urination
Fatigue
Mild hypotension

Serious (rare):

Electrolyte imbalance (low potassium, low sodium)
Kidney or liver dysfunction
Severe allergic reactions (rash, swelling, difficulty breathing)

Precautions & Warnings

Prescription Required
Avoid during pregnancy and breastfeeding.
Use with caution in patients with kidney, liver, or heart conditions.
Regular monitoring of blood pressure, kidney function, and electrolytes is essential.
Avoid alcohol, which may worsen dizziness or low blood pressure.
Inform your doctor about all other medications, especially other antihypertensives or diuretics.

Conclusion

Telma-CT 80/12.5 Tablet (Telmisartan 80mg + Chlorthalidone 12.5mg) provides strong dual-action therapy for effective blood pressure management. Combining ARB and diuretic mechanisms, it ensures optimal control of hypertension and reduces cardiovascular risks when used under proper medical supervision.